Track Outlook Therapeutics's receivables ($2.7T) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Outlook Therapeutics (OTLK) currently reports a receivables of $2.7T as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Outlook Therapeutics's receivables history and peer comparisons.
Outlook Therapeutics's receivables changed from $0 to $2.7T (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Outlook Therapeutics reported $2.7T in receivables as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $2.7T, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Outlook Therapeutics, and consider following OTLK for alerts when major investors trade the stock.
Outlook Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $2.7T. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OTLK with unrelated industries.